Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By
Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy
Conference
ECCO 2022
Trial
Phase 2, GALAXI-1
Subcutaneous guselkumab maintenance therapy achieved high efficacy rates in participants with Crohn’s disease (CD) after 2 years of follow-up in the treat-through, phase 2 GALAXI-1 study. The safety profile was favourable in this population and consistent with the safety profile of guselkumab in approved indications. Phase 3 studies assessing guselkumab in CD are currently running. The phase 2 GALAXI-1 trial (NCT03466411) randomised participants with moderately to severely active CD, who failed on prior conventional and/or biologic therapies, to 200 mg guselkumab, 600 mg guselkumab, 1,200 mg guselkumab, or placebo (intravenous, every 4 weeks). The results from the 12-week induction study demonstrated that guselkumab is associated with significantly improved clinical outcomes compared with placebo, according to Prof. Silvio Danese (Vita-Sa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on